Innogene KRX:344860KOSDAQ
이노진 · Korean news coverage and regulatory filings, organized.
Articles, 24h0
Articles, 7 days0
DART filings, 7 days0
Articles tracked0since Sep 11
In Q2 2026, Innogene reported revenue of ₩4.8bn, up 153.1% year on year, and an operating loss of ₩545m. Innogene (이노진) appeared in 0 Korean news articles and 0 DART filings over the past seven days.
Innogene quarterly results separate, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩4.8bn | +153.1% | −₩545m margin −11.4% | −₩487m |
| Q1 2026 | ₩2.6bn | +46.6% | −₩176m margin −6.8% | −₩96m |
| Q4 2025 derived | ₩2.4bn | +17.5% | ₩109m margin 4.5% | ₩211m |
| Q3 2025 | ₩2.1bn | +11.7% | −₩30m margin −1.4% | ₩59m |
| Q2 2025 | ₩1.9bn | -35.5% | −₩48m margin −2.5% | −₩28m |
| Q1 2025 | ₩1.8bn | -13.4% | −₩27m margin −1.5% | ₩45m |
| Q4 2024 derived | ₩2.1bn | -40.1% | ₩33m margin 1.6% | ₩152m |
| Q3 2024 | ₩1.9bn | -9.5% | ₩21m margin 1.1% | ₩97m |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.
Innogene top stories 2 weeks, by number of outlets
No story covered by multiple outlets in the past two weeks.
Latest Innogene news Korean headlines
No articles yet.